KR20120083359A - ＥｐＣＡＭｘＣＤ３ 이중특이성 항체를 투여하기 위한 투약 용법 - Google Patents

ＥｐＣＡＭｘＣＤ３ 이중특이성 항체를 투여하기 위한 투약 용법 Download PDF

Info

Publication number
KR20120083359A
KR20120083359A KR1020127007677A KR20127007677A KR20120083359A KR 20120083359 A KR20120083359 A KR 20120083359A KR 1020127007677 A KR1020127007677 A KR 1020127007677A KR 20127007677 A KR20127007677 A KR 20127007677A KR 20120083359 A KR20120083359 A KR 20120083359A
Authority
KR
South Korea
Prior art keywords
bispecific antibody
dose
epcamxcd3 bispecific
period
epcamxcd3
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020127007677A
Other languages
English (en)
Korean (ko)
Inventor
저할드 주그메이어
피터 쿠퍼
도미니크 뤼팅거
사비네 카우비즈취
Original Assignee
마이크로메트 에이지
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 마이크로메트 에이지 filed Critical 마이크로메트 에이지
Publication of KR20120083359A publication Critical patent/KR20120083359A/ko
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
KR1020127007677A 2009-09-18 2010-09-20 ＥｐＣＡＭｘＣＤ３ 이중특이성 항체를 투여하기 위한 투약 용법 Withdrawn KR20120083359A (ko)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US24365109P 2009-09-18 2009-09-18
EP09170715.8 2009-09-18
US61/243,651 2009-09-18
EP09170715 2009-09-18
US34414710P 2010-06-01 2010-06-01
US61/344,147 2010-06-01
EP10164596 2010-06-01
EP10164596.8 2010-06-01

Publications (1)

Publication Number Publication Date
KR20120083359A true KR20120083359A (ko) 2012-07-25

Family

ID=43127167

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020127007677A Withdrawn KR20120083359A (ko) 2009-09-18 2010-09-20 ＥｐＣＡＭｘＣＤ３ 이중특이성 항체를 투여하기 위한 투약 용법

Country Status (15)

Country Link
US (1) US20120244161A1 (enExample)
EP (1) EP2477653A1 (enExample)
JP (1) JP2013505223A (enExample)
KR (1) KR20120083359A (enExample)
CN (1) CN102711825A (enExample)
AU (1) AU2010297258A1 (enExample)
BR (1) BR112012008345A2 (enExample)
CA (1) CA2774732A1 (enExample)
IL (1) IL218637A0 (enExample)
IN (1) IN2012DN03172A (enExample)
MX (1) MX2012003175A (enExample)
NZ (1) NZ598601A (enExample)
RU (1) RU2012115480A (enExample)
SG (2) SG10201405434VA (enExample)
WO (1) WO2011033105A1 (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012158818A2 (en) 2011-05-16 2012-11-22 Fabion Pharmaceuticals, Inc. Multi-specific fab fusion proteins and methods of use
AU2012350429A1 (en) 2011-12-09 2013-07-11 Amgen Research (Munich) Gmbh Prevention of adverse effects caused by EpCAMxCD3 bispecific antibodies
GB201302447D0 (en) 2013-02-12 2013-03-27 Oxford Biotherapeutics Ltd Therapeutic and diagnostic target
FI3889173T3 (fi) 2013-02-15 2023-10-02 Bioverativ Therapeutics Inc Optimoitu tekijä viii:n geeni
JP6499087B2 (ja) 2013-02-26 2019-04-10 ロシュ グリクアート アーゲー 二重特異性ｔ細胞活性化抗原結合分子
AU2015204766B2 (en) * 2014-01-08 2020-08-13 The Board Of Trustees Of The Leland Stanford Junior University Targeted therapy for small cell lung cancer
WO2016004113A1 (en) 2014-06-30 2016-01-07 Biogen Ma Inc. Optimized factor ix gene
IL319047A (en) 2015-08-28 2025-04-01 Amunix Operating Inc Chimeric polypeptide composition and methods for its preparation and use
EP3903818A1 (en) * 2015-11-19 2021-11-03 Revitope Limited Functional antibody fragment complementation for a two-components system for redirected killing of unwanted cells
KR20180118659A (ko) 2016-02-01 2018-10-31 바이오버라티브 테라퓨틱스 인크. 최적화된 viii 인자 유전자
US12128102B2 (en) 2016-03-08 2024-10-29 Takeda Pharmaceutical Company Limited Constrained conditionally activated binding proteins
JP7034489B2 (ja) 2016-03-15 2022-03-14 アイタブメッド （エイチケイ） リミテッド 多重特異性Ｆａｂ融合タンパクおよびその使用
WO2017167350A1 (en) * 2016-03-30 2017-10-05 Horst Lindhofer Multispecific antibodies for use in the treatment of a neoplasm of the urinary tract
EP3409322A1 (en) * 2017-06-01 2018-12-05 F. Hoffmann-La Roche AG Treatment method
WO2019051102A2 (en) 2017-09-08 2019-03-14 Maverick Therapeutics, Inc. Constrained conditionally activated binding proteins
US12460000B2 (en) 2018-09-07 2025-11-04 Itabmed (Hk) Limited Anti-CD19 and anti-CD3 bispecific antigen binding proteins and uses thereof
WO2020132810A1 (en) 2018-12-24 2020-07-02 Generon (Shanghai) Corporation Ltd. Multispecific antigen binding proteins capable of binding cd19 and cd3, and use thereof
WO2020181140A1 (en) 2019-03-05 2020-09-10 Maverick Therapeutics, Inc. Constrained conditionally activated binding proteins
US12403164B2 (en) 2019-09-30 2025-09-02 Bioverativ Therapeutics Inc. Lentiviral vector formulations
KR20230074703A (ko) 2020-06-24 2023-05-31 바이오버라티브 테라퓨틱스 인크. 유리 인자 viii을 상기 단백질이 발현되도록 변형된 렌티바이러스 벡터의 제제로부터 제거하는 방법
JP2024540461A (ja) * 2021-11-19 2024-10-31 武▲漢▼友芝友生物制▲薬▼股▲ふん▼有限公司 二重特異性抗体及びその用途

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU612370B2 (en) 1987-05-21 1991-07-11 Micromet Ag Targeted multifunctional proteins
ZA200601699B (en) 2003-10-16 2007-05-30 Micromet Ag Multispecific deimmunized CD3-binders
ES2417065T3 (es) * 2005-04-26 2013-08-05 Trion Pharma Gmbh Combinación de anticuerpos con glucocorticoides para el tratamiento del cáncer

Also Published As

Publication number Publication date
SG10201405434VA (en) 2014-10-30
CA2774732A1 (en) 2011-03-24
WO2011033105A1 (en) 2011-03-24
US20120244161A1 (en) 2012-09-27
JP2013505223A (ja) 2013-02-14
BR112012008345A2 (pt) 2016-08-09
IL218637A0 (en) 2012-05-31
RU2012115480A (ru) 2013-10-27
CN102711825A (zh) 2012-10-03
AU2010297258A1 (en) 2012-03-29
EP2477653A1 (en) 2012-07-25
IN2012DN03172A (enExample) 2015-09-25
SG179027A1 (en) 2012-04-27
MX2012003175A (es) 2012-04-11
NZ598601A (en) 2014-05-30

Similar Documents

Publication Publication Date Title
US20120244161A1 (en) DOSAGE REGIMEN FOR ADMINISTERING AN EpCAMxCD3 BISPECIFIC ANTIBODY
JP2016534090A (ja) Ｃｄ３８アゴニストの医学的使用
KR20170007750A (ko) Ｈｐｖ-음성 암의 치료를 위한 ｐｄｌ-1의 길항제 및 ｐｄ-1의 길항제
CN112004828B (zh) 头颈癌的治疗
CN114026126A (zh) 抗半乳糖凝集素-9抗体及其用途
KR102947706B1 (ko) 암 치료를 위한 제약 조합물
AU2018353432A1 (en) Combination product for the treatment of cancer
WO2022232641A1 (en) Anti-galectin-9 antibodies and therapeutic uses thereof
CN109793892B (zh) 一种抗pd-1抗体在制备治疗食管癌的药物中的用途
TW202120550A (zh) 雙特異性蛋白質
KR20250116794A (ko) 항-ctla4 항체를 펨브롤리주맙과 조합하여 사용하여 암을 치료하는 방법
US20260085119A1 (en) Methods for treating cancer using anti-ctla4 antibodies
RU2833461C1 (ru) Способы лечения рака шейки матки путем введения инибитора pd-1
KR20260011225A (ko) 활성화 가능한 항-ctla4 항체를 펨브롤리주맙과 조합하여 사용하여 암을 치료하는 방법
KR20240082393A (ko) 항-갈렉틴-9 항체 및 이의 치료적 용도
WO2025140324A1 (zh) 抗pd-1抗体联合化疗剂在治疗肿瘤中的用途
WO2025021073A1 (zh) 抗Nectin4抗体药物偶联物和抗PD-1抗体的药物组合以及其用途
HK40128545A (zh) 抗pd-1抗体联合化疗剂在治疗肿瘤中的用途
CN115607663A (zh) 抗pd-1抗体在治疗原发纵隔大b细胞淋巴瘤中的应用
HK40069657A (en) Anti-galectin-9 antibodies and uses thereof
NZ729207A (en) Neutralization of inhibitory pathways in lymphocytes
NZ729207B2 (en) Neutralization of inhibitory pathways in lymphocytes

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20120323

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PC1203 Withdrawal of no request for examination
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid